Amniotic and Umbilical Cord Tissue Allografts: A Physician's Guide to Product Selection

Introduction: Understanding Birth Tissue Products

Birth tissue-derived products—including amniotic membrane, umbilical cord tissue, and related materials—have become increasingly common in regenerative medicine and wound care. These products are marketed for applications ranging from chronic wound coverage to orthopedic procedures, often with claims about growth factors, cytokines, and even stem cells.

But not all birth tissue products are equal. Processing methods dramatically affect what remains in the final product. Regulatory pathways vary significantly. And quality differences between manufacturers can impact clinical outcomes.

This guide provides the practical knowledge physicians need to evaluate, select, and use birth tissue allografts appropriately.

Overview of Birth Tissue-Derived Products

Amniotic Membrane Products

The amniotic membrane is the innermost layer of the fetal membranes, consisting of:

Epithelial layer: Contains specialized cells with documented anti-inflammatory and anti-scarring properties.

Basement membrane: Rich in collagen types IV and VII, laminin, and fibronectin—components that support cell attachment and migration.

Compact layer: Dense connective tissue providing structural support.

Clinical history: Amniotic membrane has been used in ophthalmology since the 1940s, providing decades of safety data for appropriate applications.

Umbilical Cord Tissue Products

The umbilical cord contains several potentially useful tissues:

Wharton's jelly: A gelatinous substance rich in extracellular matrix components, including hyaluronic acid, collagen, and various growth factors.

Umbilical vein and arteries: Sources of endothelial and smooth muscle cells (though these are not typically preserved in commercial products).

Amniotic epithelium: The outer covering of the cord, continuous with the amniotic membrane.

Chorion and Placental Products

Some manufacturers also process:

Chorion: The outer fetal membrane, thicker than amnion but with different properties.

Placental tissue: Contains extracellular matrix and potentially various growth factors.

Amniotic fluid: Processed for purported growth factor content.

Processing Methods and Their Impact

This is perhaps the most important section of this guide. How a product is processed determines what biological activity remains.

Fresh vs. Preserved Products

Fresh tissue (rare in commercial products):

• Maximal preservation of viable cells
• Very short shelf life (days)
• Requires careful cold chain management
• Limited commercial availability

Preserved tissue (most commercial products):

• Extended shelf life (months to years)
• Easier storage and distribution
• Variable preservation of biological activity
• Multiple preservation methods with different effects

Cryopreservation

Freezing tissue preserves some cellular viability but with important limitations:

Slow freezing with cryoprotectants:

• Can preserve some viable cells
• Requires proper storage (-80°C or colder)
• Cell viability decreases over time
• Thawing procedure affects outcome

Reality check: Even well-cryopreserved products typically have low viable cell counts compared to fresh tissue. Claims of "millions of viable cells" should be verified with third-party testing data.

Dehydration

Removing water from tissue extends shelf life but eliminates viable cells:

Air drying / lyophilization (freeze-drying):

• Room temperature storage possible
• Long shelf life (years)
• No viable cells remain
• ECM structure may be preserved
• Some growth factors may remain bound to ECM

What remains: Dehydrated products are essentially scaffolds with residual ECM components. They can provide structural support and may deliver some bioactive molecules, but they don't contain living cells.

Decellularization

Some products are intentionally decellularized to reduce immunogenicity:

Purpose: Remove cellular components while preserving ECM architecture.

Result: A scaffold without cells or cellular remnants.

Trade-off: Removes potentially beneficial cell-derived factors along with immunogenic components.

Impact Summary

| Processing Method | Viable Cells | ECM Preserved | Growth Factors | Shelf Life | |-------------------|--------------|---------------|----------------|------------| | Fresh | Yes | Yes | Yes | Days | | Cryopreserved | Some | Yes | Yes | Months | | Dehydrated | No | Partial | Some | Years | | Decellularized | No | Yes | Variable | Years |

Regulatory Pathway: 21 CFR Part 1271

Birth tissue products are regulated under 21 CFR Part 1271, which governs human cells, tissues, and cellular and tissue-based products (HCT/Ps).

Section 361 Requirements

To qualify for the less stringent 361 pathway, products must meet ALL criteria:

1. Minimal manipulation:

• Processing cannot alter the original relevant characteristics of the tissue
• For structural tissues (like amniotic membrane used as a wound covering), this means preserving physical integrity
• For non-structural tissues, this means preserving biological characteristics

2. Homologous use:

• The product must be used for the same basic function in the recipient as in the donor
• Amniotic membrane as a wound barrier = homologous (it served as a barrier in utero)
• Amniotic membrane marketed to "regenerate cartilage" = likely non-homologous

3. Not combined with another article (except for water, crystalloids, sterilizing/preserving agents, or storage solutions)

4. Either:

• Does not have a systemic effect and is not dependent on metabolic activity of living cells, OR
• Is for autologous use, use in first/second-degree relatives, or reproductive use

What This Means Clinically

Compliant 361 products:

• Structural wound coverings
• Surgical barriers and membranes
• Applications where the tissue performs the same function as in the body

Products requiring 351 approval (BLA):

• Claims of treating, curing, or preventing disease
• Systemic effects from cellular activity
• Non-homologous applications

Gray areas:

• Orthopedic injections claiming tissue regeneration
• Products marketed for anti-aging or cosmetic effects
• Applications beyond structural barrier function

What's Actually in These Products?

ECM Components (Preserved in Most Products)

Collagens:

• Types I, III, IV, V, VI, and VII
• Provide structural scaffold
• Support cell attachment

Glycoproteins:

• Laminin, fibronectin
• Cell adhesion and migration signals

Proteoglycans:

• Decorin, biglycan
• Growth factor binding and presentation

Hyaluronic acid:

• Hydration and viscoelastic properties
• Cell migration support

Growth Factors (Variable Preservation)

Common factors reported in birth tissue products:

• EGF (epidermal growth factor)
• FGF (fibroblast growth factor)
• TGF-β (transforming growth factor-beta)
• PDGF (platelet-derived growth factor)
• VEGF (vascular endothelial growth factor)

Important caveat: Growth factor content varies widely based on:

• Source tissue
• Donor variability
• Processing method
• Storage conditions
• Time since processing

Published growth factor concentrations may not reflect what's in the product you receive.

What's NOT in Most Commercial Products

Despite marketing implications, most commercial birth tissue products do NOT contain:

Viable stem cells: Processing destroys or removes cells in most products.

Therapeutic cell populations: Even "cell-containing" products have low counts.

Consistent growth factor doses: Variability is substantial.

AATB Accreditation: Why It Matters

The American Association of Tissue Banks (AATB) sets standards for tissue banking. AATB accreditation indicates:

Donor Screening

• Comprehensive medical and social history review
• Physical assessment of the donor
• Risk factor evaluation per FDA requirements

Infectious Disease Testing

• FDA-required panel of tests
• Licensed laboratories
• Documented testing protocols

Processing Standards

• Validated procedures
• Environmental controls
• Equipment qualification

Quality Systems

• Standard operating procedures
• Training and competency verification
• Deviation management
• Traceability systems

What AATB Accreditation Doesn't Guarantee

• Specific product efficacy
• Growth factor content
• Viable cell counts
• Clinical outcomes

Bottom line: AATB accreditation is necessary but not sufficient. It ensures safety standards but doesn't verify therapeutic claims.

How to Evaluate Manufacturer Quality

Questions to Ask

Regulatory status:

• Is the product registered with FDA as a 361 HCT/P?
• Can they provide their FDA registration number?
• Have they received any FDA warning letters?

Tissue sourcing:

• Is the tissue bank AATB accredited?
• Where is tissue recovered?
• What donor screening protocols are followed?

Processing:

• What preservation method is used?
• Is processing performed in cGMP-compliant facilities?
• Can they provide validation data for their process?

Quality testing:

• What testing is performed on each lot?
• Are results available for review?
• Is testing performed by independent labs?

Product characterization:

• What is actually in the product?
• Can they provide certificates of analysis?
• How is lot-to-lot variability managed?

Red Flags

Avoid products/manufacturers that:

• Make disease treatment claims without FDA approval
• Cannot provide regulatory documentation
• Use non-AATB-accredited tissue sources
• Make stem cell claims for processed products
• Lack transparency about processing methods
• Cannot provide quality testing data

Clinical Applications Across Specialties

Wound Care

Established applications:

• Chronic non-healing wounds (diabetic foot ulcers, venous leg ulcers)
• Partial-thickness burns
• Surgical wound coverage
• Dehisced wounds

Evidence level: Good evidence for certain products in specific indications, particularly Medicare LCD-covered applications.

Ophthalmology

Long-established applications:

• Corneal surface reconstruction
• Pterygium surgery
• Limbal stem cell deficiency
• Persistent epithelial defects

Evidence level: Decades of clinical use with well-documented outcomes.

Orthopedics/Sports Medicine

Emerging applications:

• Tendon augmentation
• Cartilage lesion coverage
• Joint injections

Evidence level: Limited controlled trial data; use based on theoretical benefits and case reports.

Surgical Applications

Barrier and coverage applications:

• Adhesion prevention
• Soft tissue reinforcement
• Dural repair

Evidence level: Varies by specific application; some have established use history.

Storage and Handling Requirements

Temperature Requirements

Cryopreserved products:

• Store at -80°C (some at -20°C or colder)
• Monitor freezer temperature continuously
• Have backup storage available
• Follow specific thawing protocols

Dehydrated/ambient products:

• Room temperature storage (typically 15-25°C)
• Protect from moisture
• Keep in original packaging until use

Shelf Life

• Check expiration dates before use
• Implement FIFO (first in, first out) inventory management
• Don't use expired products

Handling at Time of Use

• Follow manufacturer instructions precisely
• Maintain sterility throughout handling
• Document lot numbers in patient records
• Report any quality concerns to manufacturer

Making the Right Product Selection

Decision Framework

Step 1: Define the clinical need

• What function should the product serve?
• What tissue properties are required?

Step 2: Evaluate regulatory compliance

• Is the intended use homologous (361 appropriate)?
• Does the manufacturer have clear regulatory status?

Step 3: Assess quality indicators

• AATB-accredited source?
• cGMP manufacturing?
• Available quality documentation?

Step 4: Consider practical factors

• Storage capabilities at your facility
• Shelf life and usage patterns
• Cost and reimbursement

Step 5: Evaluate manufacturer support

• Clinical education available?
• Responsive customer service?
• Documentation assistance?

Conclusion

Birth tissue allografts offer genuine clinical utility when selected and used appropriately. They provide ECM scaffolding, may deliver residual growth factors, and have established applications in wound care, ophthalmology, and surgery.

However, not all products are equivalent. Processing methods dramatically affect final product composition. Regulatory compliance varies between manufacturers. And marketing claims often exceed evidence.

Physicians can navigate this landscape successfully by:

• Understanding what's actually in different product types
• Verifying regulatory status and quality credentials
• Matching products to appropriate clinical applications
• Setting realistic expectations for patients

At Hawk Medical, we've carefully selected tissue allograft partners who meet our standards for quality, compliance, and transparency. We're happy to share documentation and help you evaluate products for your specific needs.

Ready to explore tissue allograft options for your practice? Contact us for information on our portfolio of AATB-accredited, FDA-compliant tissue products.